SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2026)
SAB Biotherapeutics (SABS) posted Change in Account Payables of $114119.0 for Q1 2026, down 64.84% on a QoQ basis from $324527.0 in Q4 2025, and down 83.32% year-over-year from $684171.0 in Q1 2025.
SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Change in Account Payables history runs 6 years deep, the most recent figure standing at $114119.0 for Q1 2026.
- Quarterly Change in Account Payables fell 83.32% year-over-year to $114119.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $912741.0 (down 33.09% YoY) and the FY2025 annual result came in at $1.5 million, up 60.59% from the prior year.
- Change in Account Payables was $114119.0 for Q1 2026 at SAB Biotherapeutics, down from $324527.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $684171.0 in Q1 2025 and bottomed at -$2.2 million in Q1 2023.
- A 5-year average of -$11490.8 and a median of $124368.5 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables jumped 3216.08% — and 2023, when it tumbled 527.33%.
- SAB Biotherapeutics' Change in Account Payables stood at -$487425.0 in 2022, then soared by 78.3% to -$105773.0 in 2023, then soared by 658.16% to $590385.0 in 2024, then slumped by 45.03% to $324527.0 in 2025, then sank by 64.84% to $114119.0 in 2026.
- Business Quant data shows SABS's Change in Account Payables at $114119.0 in Q1 2026, $324527.0 in Q4 2025, and $335924.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 114,119.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114,119.00 |
| Mar 31, 2026 | 114,119.00 |
| Dec 31, 2025 | 324,527.00 |
| Dec 31, 2025 | 324,527.00 |
| Sep 30, 2025 | 335,924.00 |
| Sep 30, 2025 | 335,924.00 |
| Jun 30, 2025 | 138,171.00 |
| Jun 30, 2025 | 138,171.00 |
| Mar 31, 2025 | 684,171.00 |
| Mar 31, 2025 | 684,171.00 |
| Dec 31, 2024 | 590,385.00 |
| Dec 31, 2024 | 590,385.00 |
| Sep 30, 2024 | 134,618.00 |
| Sep 30, 2024 | 134,618.00 |
| Jun 30, 2024 | -45,037.00 |
| Jun 30, 2024 | -45,037.00 |
| Mar 31, 2024 | 243,357.00 |
| Mar 31, 2024 | 243,357.00 |
| Dec 31, 2023 | -105,773.00 |
| Dec 31, 2023 | -105,773.00 |